Latigo Biotherapeutics, a Thousand Oaks-based biotech firm that was originally founded by Westlake Village BioPartners, emerged from stealth mode on Feb. 14, announcing $135 million in Series A financing. Latigo is a clinical-stage biotechnology company looking to develop non-opioid pain medicines that target pain at its source, according to a press release. Proceeds from the
Kin Grows Revenue by 53% Year-over-year, Records Positive Full-year Operating Income tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Kin Grows Revenue by 53% Year-over-year, Records Positive Full-year Operating Income tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Latigo Biotherapeutics emerged from
stealth mode on Wednesday and said it had raised $135 million in
series A funding to advance clinical trials of its non-opioid
pain treatments, including a drug.